

# COVID-19 Therapeutics Checklist for Shelter and Correctional Settings

8/5/2022

## Overview

- This resource is intended for community-based facilities that offer congregate living, dining, or programming to people experiencing homelessness, people with temporary or transitional housing needs, or people that are justice-involved or otherwise living in a Department of Corrections (DOC)-licensed facility. Examples include homeless service settings and encampments, jails, prisons, DOC-licensed correctional facilities, juvenile detention centers, domestic violence shelters, youth shelters, transitional housing, permanent supportive housing, unlicensed sober homes, halfway houses, and board and lodges.
- Several medications are authorized for use in treating COVID-19 and are effective at reducing severe health outcomes among people most likely to get very sick from COVID-19.
- COVID-19 medications are available for patients who:
  - Have mild to moderate symptoms,
  - Are not in the hospital,
  - Have had symptoms for fewer than seven days, and
  - Are at high risk for severe illness from COVID-19.
- The Centers for Disease Control and Prevention (CDC) recommends that congregate living facilities assess residents' risk for severe health outcomes from COVID-19 and ensure timely treatment after infection for those who are eligible for COVID-19 therapeutics.
  - Facilities that do not have a health care provider on site should have a plan for referring residents to offsite care where they can be assessed for eligibility and receive COVID-19 therapeutics when eligible.
  - Visit [CDC Guidance on Prevention and Management of COVID-19 in Correctional and Detention Facilities \(www.cdc.gov/coronavirus/2019-ncov/community/correction-detention/guidance-correctional-detention.html\)](https://www.cdc.gov/coronavirus/2019-ncov/community/correction-detention/guidance-correctional-detention.html).
- This document outlines steps for accessing COVID-19 therapeutics and includes a list of resources to support high-risk congregate living facilities in helping eligible residents access COVID-19 medications.

## Facility checklist for connecting residents to COVID-19 therapeutics

Step	Facility requirements	Considerations	Resources and Guidance
<p><b>1. Test resident for COVID-19</b></p>	<ul style="list-style-type: none"> <li><input type="checkbox"/> Access to rapid tests or access to lab-based PCR tests with fast turnaround (&lt;24 hours)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Consider COVID-19 medications for those who are at high risk for severe illness from COVID-19.</li> <li>▪ Rapid test turnaround is critical – oral antivirals must be administered within 5 days of symptom onset.</li> <li>▪ Patient must have a COVID-19 infection confirmed either by RT-PCR or by antigen testing (not serology).</li> <li>▪ Home test or a picture of a home test result may be acceptable.</li> <li>▪ Patient must have at least one COVID-19 symptom to be eligible for therapeutics.</li> </ul>	<ul style="list-style-type: none"> <li>▪ Visit <a href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html">CDC: People with Certain Medical Conditions (www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)</a> for a full list of factors that may put someone at high risk</li> <li>▪ <a href="https://www.health.state.mn.us/diseases/coronavirus/testcong.pdf">COVID-19 Testing and Case Reporting Resources for Shelter and Correctional Settings (www.health.state.mn.us/diseases/coronavirus/testcong.pdf)</a> (lab based and rapid tests)</li> <li>▪ <a href="https://www.health.state.mn.us/diseases/coronavirus/testsites/index.html">COVID-19 Testing (www.health.state.mn.us/diseases/coronavirus/testsites/index.html)</a> resources for community members</li> <li>▪ <a href="https://mn.gov/admin/business/covid-testing-contract/">MN Dept of Administration: COVID-19 Testing Master Contract Program (https://mn.gov/admin/business/covid-testing-contract/)</a></li> <li>▪ Contact <a href="mailto:Health.R-congregate@state.mn.us">Health.R-congregate@state.mn.us</a> for additional support identifying testing resources</li> </ul>
<p><b>2. Assess patient for basic eligibility and interest in therapeutics</b></p>	<ul style="list-style-type: none"> <li><input type="checkbox"/> Staff are aware of basic eligibility criteria</li> <li><input type="checkbox"/> Staff have educational information to provide to patients about therapeutics</li> </ul>	<ul style="list-style-type: none"> <li>▪ Staff should be able to explain options in simple language, present risks/EUA, and be prepared to refer to a medical provider if patient is interested and meets basic eligibility criteria, which include:                             <ul style="list-style-type: none"> <li>▪ Confirmed COVID-19 infection.</li> <li>▪ At least one COVID-19 symptom.</li> <li>▪ Duration of symptoms is within treatment window (within 5 days of symptom onset).</li> <li>▪ Patient is interested in pursuing therapeutics.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>▪ <a href="https://www.health.state.mn.us/diseases/coronavirus/medsantiviral.pdf">COVID-19 Medications Oral Antivirals (www.health.state.mn.us/diseases/coronavirus/medsantiviral.pdf)</a> handout for patients about COVID-19 antivirals</li> <li>▪ <a href="https://www.health.state.mn.us/diseases/coronavirus/meds.html">COVID-19 Medications (www.health.state.mn.us/diseases/coronavirus/meds.html)</a> information for patients about different types of COVID-19 medications</li> <li>▪ <a href="https://www.health.state.mn.us/diseases/coronavirus/hcp/antivirals.html">Antiviral Therapy Resources for Providers: COVID-19 (www.health.state.mn.us/diseases/coronavirus/hcp/antivirals.html)</a> is a compilation of resources for</li> </ul>

COVID-19 THERAPEUTICS CHECKLIST FOR HIGH-RISK CONGREGATE LIVING FACILITIES

Step	Facility requirements	Considerations	Resources and Guidance
		<ul style="list-style-type: none"> <li>▪ Refer patient to medical provider to conduct clinical assessment and prescribe appropriate medication.</li> <li>▪ It is helpful if staff can get a patient medication list for the provider to review.</li> </ul>	<p>determining eligibility and prescribing outpatient treatment for acute COVID-19</p>
<p><b>3. Refer patient to a medical provider to conduct clinical assessment and prescribe medication</b></p>	<ul style="list-style-type: none"> <li><input type="checkbox"/> Provider on site to assess and prescribe OR staff to identify a provider and coordinate referral</li> <li><input type="checkbox"/> Reliable internet service and electronic devices for telehealth visits</li> </ul>	<ul style="list-style-type: none"> <li>▪ Refer to providers in the following order if possible:                             <ul style="list-style-type: none"> <li>▪ Patient’s usual provider if they have one.</li> <li>▪ Local provider who can serve as future medical home for patient and follow-up with patient.</li> </ul> </li> <li>▪ Consider timeliness of provider options to ensure that visit occurs within treatment window.</li> </ul>	<ul style="list-style-type: none"> <li>▪ Find a community health center at <a href="https://mnachc.org/community-health-centers/find-a-health-center/">MN Association of Community Health Centers (https://mnachc.org/community-health-centers/find-a-health-center/)</a></li> <li>▪ <a href="http://www.health.state.mn.us/diseases/coronavirus/materials/lowcost.html">Resources to Find Low-Cost Health Care or Get Health Insurance (www.health.state.mn.us/diseases/coronavirus/materials/lowcost.html)</a></li> </ul>
<p><b>4. Identify pharmacy to dispense medication</b></p>	<ul style="list-style-type: none"> <li><input type="checkbox"/> Access to a clinic or pharmacy with supply of COVID-19 oral antivirals</li> <li><input type="checkbox"/> Appropriate storage space for storing medication (if storing on site)</li> </ul>	<ul style="list-style-type: none"> <li>▪ The following facilities have access to COVID-19 therapeutic products through the federal government and/or the state:                             <ul style="list-style-type: none"> <li>▪ Federal and State designated Test to Treat Sites (provide testing, clinic visit, prescribing, and dispensing under one roof).</li> <li>▪ Retail pharmacies participating in the Federal Retail Pharmacy Program (FRPTP).</li> <li>▪ HRSA (Health Resources and Services Administration) supported health centers.</li> <li>▪ Non FRPTP or HRSA supported facilities may request to be onboarded to receive allocations via the state.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>▪ <a href="http://www.health.state.mn.us/diseases/coronavirus/hcp/medsaccess.html">Where to Access Oral Antiviral Therapy in Minnesota (www.health.state.mn.us/diseases/coronavirus/hcp/medsaccess.html)</a></li> <li>▪ <a href="https://aspr.hhs.gov/TestToTreat/Pages/default.aspx">HHS ASPR: COVID-19 Test to Treat Locator (https://aspr.hhs.gov/TestToTreat/Pages/default.aspx)</a></li> <li>▪ <a href="http://www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/participating-pharmacies.html">CDC: Pharmacies Participating in the Federal Retail Pharmacy Program (www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/participating-pharmacies.html)</a></li> <li>▪ <a href="https://findahealthcenter.hrsa.gov/">HRSA: Find a Health Center (https://findahealthcenter.hrsa.gov/)</a></li> <li>▪ <a href="https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/">ASPR: COVID-19 Therapeutics Locator (https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/)</a> (for provider use)</li> <li>▪ If interested in ordering a supply of therapeutics to dispense at your facility, submit the following forms:</li> </ul>

COVID-19 THERAPEUTICS CHECKLIST FOR HIGH-RISK CONGREGATE LIVING FACILITIES

Step	Facility requirements	Considerations	Resources and Guidance
			<p>For facilities that do not have an HPOP account:</p> <ul style="list-style-type: none"> <li>▪ <a href="https://redcap.health.state.mn.us/redcap/surveys/?s=C4F78MFMN43E74WY">Oral Antivirals Interest Survey (https://redcap.health.state.mn.us/redcap/surveys/?s=C4F78MFMN43E74WY)</a> (Paxlovid, renal packaged Paxlovid and/or Molnupiravir)</li> <li>▪ <a href="https://redcap.health.state.mn.us/redcap/surveys/?s=C4LHPRYLXEWDATX3">Therapeutic Evusheld Interest Survey (https://redcap.health.state.mn.us/redcap/surveys/?s=C4LHPRYLXEWDATX3)</a></li> <li>▪ <a href="https://redcap.health.state.mn.us/redcap/surveys/?s=8H9YPTACNHMTHJRT">Monoclonal Antibody Administration (https://redcap.health.state.mn.us/redcap/surveys/?s=8H9YPTACNHMTHJRT)</a></li> </ul> <p>For facilities that have an existing HPOP account:</p> <ul style="list-style-type: none"> <li>▪ <a href="https://redcap.health.state.mn.us/redcap/surveys/?s=MPRFJRDTFYE4YRDL">Antiviral Product Request Form - Molnupiravir and/or Paxlovid (https://redcap.health.state.mn.us/redcap/surveys/?s=MPRFJRDTFYE4YRDL)</a></li> <li>▪ <a href="https://redcap.health.state.mn.us/redcap/surveys/?s=WJFWAYTW79LCXTNW">Antiviral Product Request Form - Renal Paxlovid (https://redcap.health.state.mn.us/redcap/surveys/?s=WJFWAYTW79LCXTNW)</a></li> <li>▪ <a href="https://redcap.health.state.mn.us/redcap/surveys/?s=TH8FY7AFFWTJL79H">Antiviral Product Request Form - Evusheld (https://redcap.health.state.mn.us/redcap/surveys/?s=TH8FY7AFFWTJL79H)</a></li> <li>▪ <a href="https://redcap.health.state.mn.us/redcap/surveys/?s=CDK7XH3TC3">mAb Allocation Request Form (https://redcap.health.state.mn.us/redcap/surveys/?s=CDK7XH3TC3)</a> (currently bebtelovimab)</li> </ul> <ul style="list-style-type: none"> <li>▪ Contact <a href="mailto:Rebecca.Colby.C19@state.mn.us">Rebecca.Colby.C19@state.mn.us</a> or <a href="mailto:Marlee.Etchison@state.mn.us">Marlee.Etchison@state.mn.us</a> with questions about ordering COVID-19 therapeutics from state supply</li> </ul>

COVID-19 THERAPEUTICS CHECKLIST FOR HIGH-RISK CONGREGATE LIVING FACILITIES

Step	Facility requirements	Considerations	Resources and Guidance
<p><b>5. Get medication to patient</b></p>	<ul style="list-style-type: none"> <li><input type="checkbox"/> Transportation to deliver medications to patient or bring patient to clinic/pharmacy</li> </ul>	<ul style="list-style-type: none"> <li>▪ Delivery is preferred if health systems or pharmacies offer it. Some clinics will mail prescriptions to patients they see at their clinics.</li> <li>▪ Keep turnaround time in mind to ensure therapeutics get to patients within the 5-day treatment window for oral antivirals.</li> </ul>	<p>Transportation resources</p> <ul style="list-style-type: none"> <li>▪ <a href="http://www.dhs.state.mn.us/main/id_008991">DHS: Nonemergency Medical Transportation (NEMT) Services (www.dhs.state.mn.us/main/id_008991)</a> for Medical Assistance members</li> <li>▪ Local Public Health.</li> <li>▪ Facilities serving people experiencing homelessness may apply for reimbursement of transportation costs through the <a href="https://mich.mn.gov/shelter-outbreak-funds">MN Interagency Council on Homelessness: Shelter Outbreak Funds (https://mich.mn.gov/shelter-outbreak-funds)</a></li> </ul>
<p><b>6. Provider follow-up with patient as needed</b></p>	<ul style="list-style-type: none"> <li><input type="checkbox"/> Staff member to coordinate patient follow up with healthcare provider as needed</li> </ul>	<ul style="list-style-type: none"> <li>▪ In some cases, people treated with Paxlovid may experience a “rebound” of symptoms or a new positive viral test between two and eight days after initial recovery. If rebound occurs, the patient should restart their isolation period and follow usual isolation protocols.</li> </ul>	<ul style="list-style-type: none"> <li>▪ CDC Health Alert Network, <a href="https://emergency.cdc.gov/han/2022/han00467.asp">COVID-19 Rebound After Paxlovid Treatment (https://emergency.cdc.gov/han/2022/han00467.asp)</a></li> </ul>



Minnesota Department of Health | [health.mn.gov](http://health.mn.gov) | 651-201-5000  
 625 Robert Street North PO Box 64975, St. Paul, MN 55164-0975

Contact [health.communications@state.mn.us](mailto:health.communications@state.mn.us) to request an alternate format.